Beijing Huafang Tianshi Biopharmaceutical Co Ltd

Phase 1b, main purpose: Evaluate the tolerability of MIL62 at different doses and dosing frequencies in subjects with lupus nephritis, determine the maximum tolerated dose and the dose and dosing frequency for Phase 2 clinical studies. Phase 2, main purpose: Evaluate and compare the complete renal remission rate of MIL62 combined with standard therapy and placebo combined with standard therapy in the treatment of lupus nephritis for 76 weeks.

Part A: MIL95 pre-stimulation dose escalation study (multiple administrations): Observe the dose-limiting toxicity (DLT) and safety of MIL95 in subjects with relapsed or refractory lymphoma and advanced malignant solid tumors, and determine the pre-stimulation dose of MIL95 in subsequent studies. Part B: MIL95 maintenance dose escalation study and extension study (multiple administrations): Observe the DLT, maximum tolerated dose (MTD) and safety of MIL95 in subjects with relapsed or refractory lymphoma and advanced malignant solid tumors, and determine the maintenance dose of MIL95 in subsequent studies.